Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non–Small Cell Lung Cancer in the Irish Healthcare Setting
Ryan W Chu, Antonio Vegas García, Conor Hickey, Derek Gerard Power, Claire Gorry
Topics & Concepts
MedicineCost-effectiveness analysisPembrolizumabLung cancerCost effectivenessPopulationIncremental cost-effectiveness ratioOncologyInternal medicineCancerImmunotherapyRisk analysis (engineering)Environmental healthCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentHealth Systems, Economic Evaluations, Quality of Life